03/24/15 - 10:39 AM EDT
Biotech CEOs are supposed to be cheerleaders for their stock, so it's noteworthy when a CEO's pocketbook indicates otherwise.READ FULL POST
03/18/15 - 05:00 PM EDT
Celgene will be starting phase III studies of mongersen in Crohn's disease -- designed to lead to the drug's approval -- by the middle of the year.READ FULL POST
03/17/15 - 10:26 AM EDT
When a biotech CEO diverts from safe, bland corporate tweets to engage in some clever competitive trolling, I stand and applaud.READ FULL POST
03/13/15 - 09:36 AM EDT
The cross-trial comparison between CTI BioPharma's pacritinib and Incyte's Jakafi looks worse than expected.READ FULL POST
03/11/15 - 10:45 AM EDT
Skin cancer patients in Britain can be treated with Merck's Keytruda before the cancer immunotherapy drug is approved there under a new early access plan announced Wednesday.READ FULL POST
03/10/15 - 10:17 AM EDT
Ocular hasn't conducted clinical trials that would demonstrate that OTX-DP is any better than eye drops in reducing swelling and pain in the eye.READ FULL POST
03/04/15 - 01:47 PM EST
The new Opdivo approval covers patients with squamous non-small cell lung cancer no longer responsive to chemotherapy, according to an announcement made the FDA.READ FULL POST
03/02/15 - 08:15 AM EST
Afrezza is "modestly effective" at reducing blood glucose and its long-term safety is unknown, according to a review of the inhaled insulin published this week by The Medical Letter.READ FULL POST
02/25/15 - 07:55 AM EST
Ampio Pharmaceuticals completed a clinical trial of its diabetic macular edema drug Optina in November, but it is just too busy to disclose results.READ FULL POST
02/20/15 - 03:47 PM EST
The U.S. launch of Orexigen's obesity pill Contrave is outpacing the competition.READ FULL POST
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.